Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Su-Peng Yeh, MD, Ming Yao, MD, Jih-Luh Tang, MD,PhD, Jin-Hwang Liu, MD PhD, Tzeon-Jye Chiou, MD, Tran-Der Tan, Po-Nan Wang, MD, Yeu-Chin Chen, MD, Wen-Li Hwang, MD, Ciyuan-jheng Wang, MD, Tsai-Yun Chen, MD, TA-Chih LIU, MD PhD, Ming-Sun Yu, MD, Tso-Fu Wang

Blood (2017) 130 (Supplement 1): 3229.

https://doi.org/10.1182/blood.V130.Suppl_1.3229.3229

Published: 2017

Journal Articles

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Yi-Jiun Su, MD, Ming-Chung Kuo, MD, Chieh-Lin Teng, MD, Tsai-Yun Chen, MD, Ming-Chun Ma, MD, Pei-Ching Hsiao, MD, Ming-Chung Wang, MD, Tung-Huei Lin, MS, Wen-Li Hwang, MD, Chih-Cheng Chen, MD, Youngsen Yang, MD, Sung-Nan Pei, MD, Yen-Min Huang, MD, Sin-Syue Li, MD, Ming-Yang Lee, MD, Hung-I Cheng, MD, Lee-Yung Shih, MD

Blood (2017) 130 (Supplement 1): 1603.

https://doi.org/10.1182/blood.V130.Suppl_1.1603.1603

Published: 2017

Journal Articles

A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia

Suporn Chuncharunee, MD, Raymond SM Wong, MD, Ponlapat Rojnuckarin, MD PhD, Cheng-Shyong Chang, MD, Kian Meng Chang, MD, Meng-Yao Lu, MD, Wen-Li Hwang, MD, Liang Piu Koh, MD, Tsai-Yun Chen, MD, Anskar YH Leung, MD, Lalita Norasetthada, MD, Shih-Chung Wang, MD, Ming-Chih Chang, MD, Kang-Hsi Wu, MD, Surapol Issaragrisil, MD

Blood (2015) 126 (23): 1217.

https://doi.org/10.1182/blood.V126.23.1217.1217

Published: 2015

Journal Articles

Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan

Ching-Yuan Kuo, MD, Po-Nan Wang, MD, Wen Li Hwang, MD, Cheng-Hwai Tzeng, MD, Li-Yuan Bai, MD, Jih-Luh Tang, MD PhD, Ming-Chih Chang, MD, Sheng-Fung Lin, MD, Tsai-Yun Chen, MD, Yeu-Chin Chen, MD, Tran-Der Tan, MD, Chih-Yi Hseih, MD, Chinjune Lin, MD, Miljkovic Darko, MD, Chang Cheng-Shyong, MD

Blood (2015) 126 (23): 1593.

https://doi.org/10.1182/blood.V126.23.1593.1593

Published: 2015

Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD

Blood (2014) 124 (21): 4544.

https://doi.org/10.1182/blood.V124.21.4544.4544

Published: 2014

NARROW

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Email alerts

ASH Publications

American Society of Hematology

Differential Impact of Conditioning Intensity on Post-Transplant Outcome of FLT3 -Mutated and FLT3 Wild Type AML in First Remission, a Report from Taiwan Bone Marrow Transplant Registry (TBMTR)

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

A Retrospective Multicenter Study to Evaluate the Efficacy of Rabbit Antithymocyte Globulin (rATG) Immunosuppressive Therapy As First-Line Treatment of Aplastic Anemia

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only